Moody National Bank Trust Division trimmed its position in shares of Novartis AG (NYSE:NVS – Get Rating) by 49.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,390 shares of the company’s stock after selling 4,353 shares during the period. Moody National Bank Trust Division’s holdings in Novartis were worth $371,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Optimum Investment Advisors grew its stake in shares of Novartis by 10.9% in the 1st quarter. Optimum Investment Advisors now owns 1,126 shares of the company’s stock valued at $99,000 after buying an additional 111 shares in the last quarter. Hanson & Doremus Investment Management grew its position in Novartis by 13.4% in the first quarter. Hanson & Doremus Investment Management now owns 972 shares of the company’s stock worth $85,000 after acquiring an additional 115 shares in the last quarter. Harbor Investment Advisory LLC increased its stake in shares of Novartis by 6.7% during the 1st quarter. Harbor Investment Advisory LLC now owns 1,935 shares of the company’s stock worth $170,000 after purchasing an additional 122 shares during the last quarter. Rossmore Private Capital raised its holdings in shares of Novartis by 2.1% during the 1st quarter. Rossmore Private Capital now owns 6,220 shares of the company’s stock valued at $546,000 after purchasing an additional 125 shares in the last quarter. Finally, Trust Co. of Oklahoma lifted its stake in shares of Novartis by 1.0% in the 1st quarter. Trust Co. of Oklahoma now owns 12,481 shares of the company’s stock valued at $1,095,000 after purchasing an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 9.14% of the company’s stock.
Novartis Stock Performance
Shares of NYSE NVS opened at $80.73 on Tuesday. The firm has a market capitalization of $178.62 billion, a price-to-earnings ratio of 7.89, a PEG ratio of 2.28 and a beta of 0.53. The company has a current ratio of 1.38, a quick ratio of 1.13 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $83.89 and a 200 day simple moving average of $85.88. Novartis AG has a one year low of $79.09 and a one year high of $94.26.
Wall Street Analyst Weigh In
NVS has been the topic of several recent research reports. Berenberg Bank lowered Novartis from a “buy” rating to a “hold” rating in a report on Wednesday, September 14th. JPMorgan Chase & Co. upped their target price on Novartis from CHF 80 to CHF 81 and gave the stock an “underweight” rating in a research report on Wednesday, July 20th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Novartis from CHF 80 to CHF 75 in a research report on Wednesday, June 29th. Kepler Capital Markets raised shares of Novartis from a “hold” rating to a “buy” rating and set a CHF 90 price objective for the company in a report on Wednesday, September 7th. Finally, Credit Suisse Group lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Thursday, September 15th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $87.00.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.